Denali Therapeutics Inc. (DNLI) Misses Q1 EPS by 3c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q1 EPS of ($0.69), $0.03 worse than the analyst estimate of ($0.66).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• GSX Techedu Inc. (GOTU) Misses Q2 EPS by 11c; offers guidance
• Materialise NV (MTLS) Reports Q2 EPS of EUR0.06
• Inhibrx Biosciences (INBX) Reiterated at Market Perform by Citizens as Ozekibart Ph1 Started